Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Cytarabine and Idarubicin in Newly Diagnosed AML
NCT00002800Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 1996
- Primary completion
- Mar 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cytarabine, idarubicin in acute myeloid leukemia (AML), chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS), sponsored by Memorial Sloan Kettering Cancer Center. Started Jul 1996; status: completed.
02
Drugs
cytarabineidarubicin
03
Conditions
acute myeloid leukemia (AML)chronic myeloid leukemia (CML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00002800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002800.